Clinical Trials on Recurrent Peritoneal Malignant Mesothelioma

Total 1038 results

University of California, San Francisco
Gilead Sciences

Suspended

Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors (PNOC025)

Brain Cancer | Malignant Brain Tumor | Brain Tumor Adult | Recurrent Brain Tumor | Progressive Malignant Brain Tumor | Brain Tumor, Pediatric

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Memorial Sloan Kettering Cancer Center
University of Pennsylvania; Dana-Farber Cancer Institute; Novartis Pharmaceuticals

Completed

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

Malignant Pleural Mesothelioma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Childhood Solid Neoplasm

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditions

United States
Roswell Park Cancer Institute
Lumeda,Inc.

Active, not recruiting

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

Malignant Mesothelioma | Non-Small Cell Lung Carcinoma | Pleural Disorder

United States
Incyte Corporation

Withdrawn

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Advanced and/or Metastatic Solid Tumors | Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer | Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Malignant Ovarian Endometrioid Tumor | Ovarian High Grade Serous Adenocarcinoma | Platinum-Sensitive Ovarian Carcinoma | Fallopian Tube High Grade Serous Adenocarcinoma and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma

United States
AstraZeneca

Recruiting

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Unresectable Pleural Mesothelioma

Denmark, Italy, Australia, Korea, Republic of, Belgium, United States, Canada, Japan, United Kingdom, China, Brazil, France, Taiwan, Spain, Norway, Switzerland, Turkey, Poland, Germany, South Africa, Netherlands
Sun Yat-sen University

Recruiting

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Pleural Mesothelioma

China
Mario Negri Institute for Pharmacological Research

Completed

Diadem to Investigate the Activity and Safety of Durvalumab (Diadem)

Pleura Mesothelioma

Italy
University Health Network, Toronto

Completed

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

Pleural Mesothelioma

Canada
M.D. Anderson Cancer Center

Recruiting

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

Small Cell Lung Cancer | Hodgkin's Lymphoma | Cervical Carcinoma | Peritoneal Mesothelioma | Pleural Mesothelioma | Neuroendocrine Carcinomas | Microsatellite High Cancers | Extrapulmonary High Grade

United States
Ira Winer

Recruiting

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Malignant Ovarian Epithelial Tumor | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian... and other conditions

United States
Istituto Oncologico Veneto IRCCS
MSD Italia S.r.l.

Not yet recruiting

Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) (CHIMERA)

Pleural Mesothelioma

Italy
NovoCure GmbH

Recruiting

TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study (TIGER Meso)

Pleural Mesothelioma

Germany, Italy
University Health Network, Toronto

Active, not recruiting

A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection (SMARTER)

Mesothelioma; Lung

Canada
Columbia University

Terminated

Trimodal Lung-Sparing Treatment of Pleural Mesothelioma

Pleural Mesothelioma

United States
University Health Network, Toronto
Eli Lilly and Company

Terminated

Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma

Mesothelioma | Pleural Mesothelioma

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers

Advanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | PALB2 Gene Mutation | ATM Gene Mutation

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIC Fallopian Tube Cancer and other conditions

Canada
University of Washington
National Cancer Institute (NCI)

Recruiting

Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Ovarian Epithelial Tumor

United States
ARCAGY/ GINECO GROUP

Completed

Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse

Ovarian Cancer | Fallopian Tube Cancer | Malignant Tumor of Peritoneum

France
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies

Peritoneal Neoplasms | Recurrent Ovarian Carcinoma | Recurrent Uterine Corpus Carcinoma | Cervical Carcinoma | Ovarian Carcinoma | Recurrent Cervical Carcinoma | Uterine Corpus Cancer | Vulvar Carcinoma | Primary Peritoneal Carcinoma | Recurrent Vulvar Carcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Incyte Corporation

Not yet recruiting

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

Recurrent Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain

Recurrent Glioblastoma | Metastatic Melanoma | Recurrent Malignant Glioma | Metastatic Malignant Neoplasm in the Brain | Recurrent Brain Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm

United States
NanoAlvand

Completed

Alvopem® (Pemetrexed) Safety Assessment

Non Small Cell Lung Cancer | Malignant Pleural Mesothelioma
Swiss Group for Clinical Cancer Research

Active, not recruiting

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

Non-small Cell Lung Cancer | Malignant Pleural Mesothelioma

Switzerland
Asbestos Diseases Research Foundation
EnGeneIC Limited

Completed

MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC

Non-Small Cell Lung Cancer | Malignant Pleural Mesothelioma

Australia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm

United States
Memorial Sloan Kettering Cancer Center

Completed

A Study of Pembrolizumab and Cryoablation in People With Mesothelioma

Lung Cancer | Unresectable Mesothelioma

United States
M.D. Anderson Cancer Center
DNAtrix, Inc.

Recruiting

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Gliosarcoma | Recurrent Anaplastic Astrocytoma | IDH1 wt Allele

United States
Marcela V. Maus, M.D.,Ph.D.

Recruiting

CARv3-TEAM-E T Cells in Glioblastoma

Glioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent Glioma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis

Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Refractory Neoplasm

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Recurrent Ovarian Low Grade Serous Adenocarcinoma | Borderline Ovarian Serous Tumor | Micropapillary Serous Carcinoma | Recurrent Primary Peritoneal Serous Adenocarcinoma

United States, United Kingdom
Sichuan University

Recruiting

Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases

Malignant Ascites | Malignant Peritoneal Effusion | Serous Cavity Metastatises

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas

Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Recurrent Gliosarcoma | Recurrent Anaplastic Astrocytoma | Recurrent Anaplastic Oligoastrocytoma | Recurrent Anaplastic Oligodendroglioma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
Jonsson Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Metastatic Malignant Female Reproductive System Neoplasm | Platinum-Resistant Malignant Female Reproductive System Neoplasm | Recurrent Malignant Female Reproductive System Neoplasm | Refractory Malignant Female Reproductive System Neoplasm

United States

Clinical Trials on Recurrent Peritoneal Malignant Mesothelioma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations